BACKGROUND: Low testosterone at the time of diagnosis of prostate cancer has been associated with a worse prognosis. Whether this is true and how to define the best treatment approach at the time of first prostate-specific antigen (PSA) failure to the authors' knowledge has not been elucidated to date and was studied herein. METHODS: Between 1995 and 2001, a total of 58 men with unfavorable-risk PC who were treated on clinical trials with radiotherapy and androgen deprivation therapy (ADT) had available testosterone levels at the time of PSA failure. Cox and Fine and Gray regressions were performed to ascertain whether low versus normal testosterone was associated with the risk of PC-specific mortality, other-cause mortality, and all-cause mortality adjusting for age, salvage ADT, and known PC prognostic factors. RESULTS: After a median follow-up of 6.68 years after PSA failure, 31 men (53.4%) had died; 10 of PC (32.3%), of which 8 of 11 (72.7%) versus 2 of 47 (4.3%) deaths occurred in men with low versus normal testosterone at the time of PSA failure, respectively. A significant increase in the risk of all-cause mortality (adjusted hazard ratio [AHR], 2.54; 95% confidence interval [95% CI], 1.04-6.21 [P 5 .04]) and PC-specific mortality (AHR, 13.71; 95% CI, 2.4-78.16 [P 5 .003]), with a reciprocal trend toward a decreased risk of other-cause mortality (AHR, 0.18; 95% CI, 0.02-1.55 [P 5 .12]) was observed in men with low versus normal testosterone. CONCLUSIONS: Low, but not necessarily castrate, testosterone levels at the time of PSA failure confer a very poor prognosis. These observations provide evidence to support testosterone testing at the time of PSA failure. Given prolonged survival when abiraterone or docetaxel is added to ADT in men with castrate-sensitive metastatic PC and possibly localized high-risk PC provides a rationale supporting their use with ADT in men with low testosterone in the setting of a phase 2 trial. Cancer 2018;124:1383-90.
INTRODUCTION
Several prospective randomized clinical trials have demonstrated that the addition of androgen deprivation therapy (ADT) to external-beam radiotherapy (RT) prolongs prostate cancer (PC)-specific and overall survival in men treated for intermediate-risk or high-risk PC. [1] [2] [3] However, despite definitive management, up to one-third of these men will experience biochemical failure. 4 The standard of care for prostate-specific antigen (PSA) failure after definitive RT is salvage ADT, most commonly using a luteinizing hormone-releasing hormone (LHRH) agonist, 5 although to the best of our knowledge no prospective, randomized trials to date have been conducted to determine a survival benefit with salvage ADT compared with observation in men with PSA-only disease recurrence. Moreover, the clinical course to metastasis and death from PC after PSA failure is quite variable. Although associated prognostic factors such as PSA doubling time (PSA DT), interval to PSA failure, and biopsy Gleason score 4, 6 have been identified, there remains a need for the determination of additional prognostic and predictive factors to further personalize optimal salvage therapy.
Therapeutic targeting of the androgen receptor signaling axis remains a mainstay of current treatment strategies. Indeed, the use of the novel antiandrogens enzalutamide and abiraterone and the chemotherapeutic agent docetaxel have been shown to prolong survival in men with metastatic castrate-resistant PC, [7] [8] [9] whereas abiraterone 10, 11 and docetaxel 12, 13 when added to standard ADT have been shown to prolong survival in men with newly diagnosed metastatic castrate-sensitive PC and possibly high-risk localized PC 11, 13, 14 compared with conventional ADT alone. Moreover, although it has been demonstrated that low testosterone at the time of presentation is associated with more aggressive tumors, poorer prognosis after radical prostatectomy, and shorter responses to ADT, [15] [16] [17] [18] to the best of our knowledge the impact of low testosterone on survival and how to define the best treatment approach at the time of first PSA failure has not been elucidated.
The objective of the current study was to evaluate men with unfavorable-risk PC who were enrolled on a prospective trial and treated with definitive RT and ADT to determine whether low testosterone at the time of first PSA failure and before the documentation of metastatic disease was associated with an increased risk of PC-specific mortality (PCSM) and all-cause mortality (ACM), adjusting for age, salvage ADT use, and known PC prognostic factors. If such an association existed, then low testosterone levels at the time of first PSA failure could be used to identify men who are optimal candidates for enrollment onto prospective trials testing the addition of novel therapeutic agents to ADT, including agents shown to prolong survival in patients with metastatic castrate-sensitive, castrate-resistant, or high-risk localized PC.
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MATERIAL AND METHODS
Patient Population and Treatment
The 58 patients in the current study were enrolled on 1 of 2 prospective clinical trials, for which a complete description of eligibility criteria, treatment specifications, and patient characteristics have been reported previously. 1, 19 In the first trial (ClinicalTrials.gov identifier NCT00002889), a total of 180 men with 1992 American Joint Commission on Cancer clinical T1c-T3cN0M0 PC were enrolled onto a phase 2 Cancer and Leukemia Group B study (CALGB 9682) evaluating the prognostic significance of endorectal magnetic resonance imaging-defined tumor volume changes in men treated with definitive RT and ADT between May 31, 1997, and April 30, 2001 . In the second study (ClinicalTrials.gov identifier NCT00116220), a total of 206 men with 1992 American Joint Commission on Cancer clinical T1b-T2bNXM0 PC were randomized to receive RT with or without 6 months of ADT between December 7, 1995, and December 27, 2001 . Only the men on the ADT arm were eligible for inclusion in the current study. For both studies, centralized pathology review was performed by a dedicated genitourinary pathologist. All 58 men in the current study were treated with RT and ADT, consisting of 6 months of an LHRH agonist (leuprolide acetate at a dose of 7.5 mg monthly or 22.5 mg every 3 months or goserelin at a dose of 3.6 mg monthly or 10.8 mg every 3 months) and a nonsteroidal antiandrogen (flutamide at a dose of 250 mg every 8 hours). External beam RT was delivered to the prostate and seminal vesicles using a 3-dimensional conformal technique, prescribed to an isocenter that received 45 grays (Gy) in 25 fractions of 1.8 Gy followed by a boost volume that received 21.6 to 22 Gy delivered in 11 to 12 fractions of 1.8 to 2.0 Gy, normalized to 95%.
A PSA rise 2 ng/mL above the nadir was achieved before the initiation of salvage therapy in all patients, thereby meeting the 2006 Phoenix definition of PSA failure after RT. 20 Salvage therapy generally consisted of an LHRH agonist. Of the subset of 180 men and 206 men, respectively, from CALGB 9682 and the RCT who experienced PSA failure and received salvage ADT, 58 men (4 from CALGB 9682 alone and54 from the RCT who also were eligible for coenrollment onto CALGB 9682) had total serum testosterone levels at the time of first PSA failure available and thereby defined the current study cohort (Fig. 1) . Serum testosterone was measured centrally using the Bayer assay (Bayer Corporation, Whippany, New Jersey), with low testosterone defined as <280 ng/dL (lower limit of normal for this assay). This retrospective review was approved by the institutional review board of the Dana-Farber Cancer Institute.
Follow-Up and Determination of the Cause of Death
In CALGB 9682, men were seen in follow-up every 6 months for 3 years and annually thereafter, whereas men in the RCT were seen every 3 months for the first 2 years, every 6 months for the subsequent 3 years, and yearly thereafter. Each follow-up visit included a history and physical examination, with serum PSA levels obtained before digital rectal examination. At the time of first PSA failure, a restaging bone scan and pelvic computed tomography scan or magnetic resonance imaging scan were obtained. No men were lost to follow-up. The cause of death was determined by the patient's primary oncologist. Death from PC was defined as those men who had castrate-resistant metastatic disease and a rising PSA despite salvage ADT regimens and/or chemotherapy at the time of death.
Statistical Analysis
Distribution and comparison of clinical characteristics
Descriptive statistics were used to report the distribution of clinical characteristics among men with low versus normal testosterone at the time of first PSA failure and are shown in Table 1 . The clinical factors including PSA DT, interval to PSA failure, age at PSA failure, and interval to salvage ADT after PSA failure had median and Original Article interquartile ranges calculated and compared across the 2 testosterone subgroups. For the continuous covariates (PSA DT, interval to PSA failure, and age at PSA failure), comparisons were evaluated using a Wilcoxon rank sum test, 21 whereas interval to salvage ADT after PSA failure and median survival were calculated using the KaplanMeier method and comparisons made using the log-rank test. 22 The categorical covariate of Gleason score (6, 7, or 8-10) was compared using a Fisher exact test. 23 
Cox and competing risks regression
Univariate and multivariate Cox 24 and Fine and Gray 25 regressions were performed to ascertain whether low versus normal testosterone was associated with the risk of PCSM, other-cause mortality (OCM), and ACM adjusting for age, salvage ADT use, and known PC prognostic factors. For the Fine and Gray competing-risks regressions, deaths due to causes other than the indicated endpoint were censored at the time of death and considered as "competing risks." For the model, time zero was the date of PSA failure and concluded by the date of death or last observation through January 22, 2015, whichever came first. The variables of low versus normal testosterone level at the time of first PSA failure and biopsy Gleason score (6, 7, or 8-10) were treated as categorical covariates with baseline groups defined as low testosterone and Gleason score 6, respectively, whereas the variables of PSA DT, age at PSA failure, and interval to PSA failure were treated as continuous covariates. The use of salvage ADT was modeled as a time-dependent covariate, given that the interval from PSA failure to the initiation of salvage ADT varied depending on when the PSA level approached 10 ng/mL as per protocol specification. Unadjusted hazard ratios (HRs) and adjusted HRs (AHRs) were calculated for each covariate with associated 95% confidence intervals (95% CIs) and P values (a 2-sided P value <.05 was considered to be statistically significant).
Estimates of ACM, PCSM, and OCM
One minus Kaplan-Meier estimates 22 of ACM and cumulative incidence estimates 26 of PCSM and OCM were calculated and graphically displayed, stratified by low or normal testosterone at the time of first PSA failure. These estimates were compared using a 2-sided Gray P value 27 for PCSM and OCM and a log-rank 2-sided P value for ACM. A 2-sided P value <.05 was considered to be statistically significant. SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina) was used for all calculations except those involving 2-sided Gray P values, for which R statistical software (version 3.2.3; R Foundation, Vienna, Austria) was used.
RESULTS
Distribution and Comparison of Clinical Characteristics
As shown in Table 1 , men with low testosterone at the time of first PSA failure (median serum testosterone of 162 ng/dL [range, 120-236 ng/dL]) were found to have less favorable clinical characteristics and median survival when compared with men with normal testosterone. Specifically, these men had a shorter median PSA DT (2.79 vs 10.59 months; P 5.001) and a greater percentage of a highest Gleason score of 8 to 10 (54.5% vs 25.5%; P 5.04). Men with low testosterone had a shorter median survival after PSA failure (4.06 vs 7.55 years; P 5.046). Among the 11 men with low testosterone at the time of PSA failure, 4 (36.4%) also had low testosterone at the time of PC diagnosis ( Fig. 1) , with testosterone levels of 205 ng/dL, 198 ng/dL, 199 ng/dL, and 211 ng/dL, respectively, and corresponding values of 127 ng/dL, 147 ng/dL, 157 ng/dL, and 201 ng/dL, respectively, at the Estimates of ACM, PCSM, and OCM stratified by low versus normal testosterone at the time of first PSA failure are shown in Figures 2A, 2B , and 2C, respectively. In men with low testosterone, there was a statistically significant increase in the estimates of ACM (P 5.046) ( Fig. 2A) and PCSM (P<.0001) (Fig. 2B) , whereas there was a reciprocal decrease in OCM that approached statistical significance (P 5.0504) (Fig. 2C) 
DISCUSSION
We observed that men with low testosterone at the time of first PSA failure had less favorable clinical characteristics, including worse survival outcomes, a significantly increased risk of ACM and PCSM, and a lower risk of OCM compared with men with normal testosterone. Specifically, of the 11 men with low testosterone at the time of first PSA failure, 8 died of PC after a median follow-up of only 6.68 years after PSA failure. These observations identify low, but not necessarily castrate, testosterone levels at the time of first PSA failure as a poor prognostic factor after definitive management with RT and combined ADT in men with unfavorable-risk PC.
The clinical significance of these observations is that they provide evidence to support testosterone testing at the time of first PSA failure as an opportunity to identify men who have a more aggressive cancer recurrence and therefore a worse prognosis. Specifically, given a rising PSA in the setting of low testosterone, meaning conventional ADT is extremely unlikely to be effective, future clinical trials in these men are warranted. Although to our knowledge docetaxel, enzalutamide, and abiraterone are not approved in the setting of nonmetastatic, castrateresistant PC, the survival benefit of abiraterone or docetaxel when added to ADT in men with castrate-sensitive metastatic PC [10] [11] [12] [13] and possibly high-risk localized PC 11, 13, 14 provides a rationale to support testing them in combination with conventional ADT in men with low testosterone at the time of first PSA failure. Specifically, in the setting of a phase 2 trial with ADT and abiraterone, enzalutamide, and/or docetaxel, men would be stratified by low or normal testosterone at the time of initial diagnosis. This stratification is supported by prior studies demonstrating that low testosterone at the time of PC diagnosis is associated with a poorer prognosis after radical prostatectomy or RT and ADT and shorter responses to salvage ADT. [15] [16] [17] [18] If a high PSA response rate (such as a decline in pretreatment PSA of >80% or more stringently achieving an undetectable PSA <0.1 ng/mL) in at least two-thirds of the study cohort is observed, this would provide the basis to support a phase 3 trial in this setting investigating standard ADT with 1 novel agents and their impact on survival.
Several points require further discussion. First, multiple investigations have shown that posttreatment response factors after RT and ADT, such as a PSA nadir >0.5 ng/mL, PSA DT <3 months, and interval to PSA failure, are not only prognostic but also are a surrogate for PCSM and/or ACM. 4, 28 However, these investigations were undertaken before recent trials demonstrating a survival advantage to abiraterone, docetaxel, and enzalutamide in patients with metastatic castrate-resistant PC, and abiraterone and docetaxel in patients with castratesensitive metastatic PC. [7] [8] [9] [10] [11] [12] [13] Therefore, the question of whether these posttreatment response factors remain surrogates for ACM in the modern salvage therapy era has yet to be elucidated. Moreover, the posttreatment factor of low testosterone at the time of first PSA failure and both a PSA nadir >0.5 ng/mL and PSA DT <3 months could be tested against one another using a metric such as the percentage of treatment effect explained by the proposed surrogate 29 to determine which candidate surrogate marker is best and most appropriate to use in future prospective trials.
Second, in the era of advanced molecular imaging for recurrent disease after primary treatment failure, including the US Food and Drug Administrationapproved ( positron emission tomography radioligands, 30 it would be of interest to explore whether men with low versus normal testosterone at the time of first PSA failure have residual or recurrent disease identified using advanced imaging by validating with biopsy. It is interesting to note that we observed in the current study that men with low testosterone at the time of PSA failure initiated salvage ADT sooner than men with normal testosterone (Table 1 ). The question of whether advanced imaging in this castrate-resistant subgroup at the time of first PSA failure can identify site(s) of residual/recurrent disease sooner when compared with standard imaging is worthy of further study.
Finally, potential limitations of the current study are the small sample size and its retrospective nature. Therefore, to provide further evidence supporting phase 2 testing of this concept, additional validation in larger data sets with mature follow-up is warranted. However, despite the small sample size, there remains a significant effect of low testosterone at the time of PSA failure as a prognostic factor, as evidenced by the increased risk of PCSM (AHR, 13.71; 95% CI, 2.4-78.16 [P 5.003]) ( Table 2 ) noted in men with low versus normal testosterone. Moreover, because 8 of the 11 men (72.7%) with low testosterone at the time of PSA failure died of PC compared with 2 of the 48 men (4.2%) with normal testosterone, this increased risk of PCSM translated into an increased risk of ACM (AHR, 2.54; 95% CI, 1.04-6.21 [P 5.04]) ( Fig. 2A) .
Conclusions
Despite the potential limitations described above, the data from the current study demonstrate that men with low, but not necessarily castrate, testosterone levels at the time of first PSA failure have a very poor prognosis. These observations provide evidence to support testosterone testing at the time of PSA failure. Moreover, given that survival is prolonged when abiraterone or docetaxel is added to ADT in men with castrate-sensitive metastatic PC and possibly in men with localized high-risk PC provides rationale to support their use with ADT in men with low testosterone at the time of first PSA failure in the setting of a phase 2 trial.
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